43P PDL1 protein expression is a prognostic factor in triple negative breast cancer

Abstract

Background: Programmed death-liangd-1(PDL1) is a molecule involved in immune evasion in breast cancer. In the phase III clinical trial of impassion 130, the PDL1 expression is a predictive biomarker for the metastatic triple-negative breast cancer therapy. To determine PD1/PDL1 expression in early stage of triple-negative breast cancer, and to analyze the relationship between their expression and prognosis. abstracts Annals of Oncology Volume 31 -Issue S2 -2020 S31